Symbols / VANI $1.22 +10.91%
VANI Chart
About
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 99.07M |
| Enterprise Value | 104.67M | Income | -26.03M | Sales | — |
| Book/sh | 0.02 | Cash/sh | 0.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | — | Forward P/E | -3.49 | PEG | — |
| P/S | — | P/B | 58.10 | P/C | — |
| EV/EBITDA | -3.90 | EV/Sales | — | Quick Ratio | 0.48 |
| Current Ratio | 0.61 | Debt/Eq | 1397.48 | LT Debt/Eq | — |
| EPS (ttm) | -0.45 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -50.05% |
| ROE | -265.02% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 81.21M |
| Shs Float | 32.56M | Short Float | 0.50% | Short Ratio | 0.76 |
| Short Interest | — | 52W High | 1.92 | 52W Low | 0.91 |
| Beta | 3.36 | Avg Volume | 315.51K | Volume | 422.96K |
| Target Price | $5.00 | Recom | None | Prev Close | $1.10 |
| Price | $1.22 | Change | 10.91% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.22
Latest analyst target
3. DCF / Fair value
$-3.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.22
Low
$4.00
High
$7.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-07 | init | HC Wainwright & Co. | — → Buy | $3 |
| 2022-12-05 | init | ThinkEquity | — → Buy | $7 |
- Insider Stock Purchases: March 16, 2026 - Quiver Quantitative Mon, 16 Mar 2026 18
- Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases 1,575,231 Shares of Stock - MarketBeat Mon, 16 Mar 2026 12
- Insider Makes Bold Move With Major Vivani Medical Stock Purchase - TipRanks ue, 17 Mar 2026 02
- Vivani Medical (VANI) Stock Analysis Report | Financials & Insights - Benzinga Japan Sat, 14 Mar 2026 18
- Vivani Medical, Inc. (NASDAQ:VANI) insiders have had a fantastic week as stock increased 17%, and they haven't stopped buying - simplywall.st Fri, 23 Jan 2026 08
- Vivani medical director Williams buys shares worth $1.68 million - Investing.com Mon, 16 Mar 2026 12
- Vivani chair backs $4.5M raise for long-acting drug implants - Stock Titan Sun, 25 Jan 2026 08
- Vivani Medical (NASDAQ:VANI) Stock Price Down 2.6% - Should You Sell? - MarketBeat hu, 12 Mar 2026 04
- Insiders hold 43% of Vivani Medical, Inc. (NASDAQ:VANI), and they've been buying recently - Yahoo Finance Fri, 05 Dec 2025 08
- Vivani Medical shares are trading higher afte... - Benzinga Mon, 16 Mar 2026 16
- Vivani Medical Stock (VANI) Opinions on Insider Purchase - Quiver Quantitative hu, 16 Oct 2025 07
- Vivani Medical (Nasdaq: VANI) expects $15.7M gross proceeds from stock offering - Stock Titan Sun, 26 Oct 2025 07
- Vivani medical director Williams buys $1.98 million in VANI stock - Investing.com hu, 16 Oct 2025 07
- Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4% - MarketBeat Sat, 14 Mar 2026 09
- Insiders Rewarded With US$1.9m Addition To Investment As Vivani Medical Stock Hits US$110m - Yahoo Finance Fri, 23 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1866492 | 1983333 | — | Purchase at price 1.03 - 1.26 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-13 00:00:00 | I |
| 1 | 1351351 | 1999999 | — | Purchase at price 1.48 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-27 00:00:00 | I |
| 2 | 1737765 | 1983334 | — | Purchase at price 1.12 - 1.26 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-15 00:00:00 | I |
| 3 | 20000 | 24600 | — | Purchase at price 1.23 per share. | MENDELSOHN AARON | Director | — | 2025-12-29 00:00:00 | D |
| 4 | 1737765 | 1983334 | — | Purchase at price 1.12 - 1.26 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-15 00:00:00 | I |
| 5 | 1737764 | 2425297 | — | Purchase at price 1.26 - 1.42 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-14 00:00:00 | I |
| 6 | 3703703 | 5999999 | — | Purchase at price 1.62 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-27 00:00:00 | I |
| 7 | 1737764 | 1983333 | — | Purchase at price 1.12 - 1.26 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-15 00:00:00 | I |
| 8 | 2068453 | 2400001 | — | Purchase at price 1.12 - 1.26 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-15 00:00:00 | I |
| 9 | 12740 | 12867 | — | Purchase at price 1.01 per share. | WILLIAMS GREGG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-16 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -24.28M | -26.61M | -20.86M | -12.98M |
| TotalUnusualItems | 6.88M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 6.88M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -23.49M | -25.65M | -13.89M | -12.77M |
| ReconciledDepreciation | 400.00K | 357.00K | 381.00K | 345.00K |
| EBITDA | -24.28M | -26.61M | -20.86M | -12.98M |
| EBIT | -24.68M | -26.96M | -21.24M | -13.32M |
| NormalizedIncome | -23.49M | -25.65M | -13.89M | -12.77M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -23.49M | -25.65M | -13.89M | -12.77M |
| TotalExpenses | 24.68M | 26.96M | 21.24M | 13.32M |
| TotalOperatingIncomeAsReported | -24.68M | -26.96M | -21.24M | -13.32M |
| DilutedAverageShares | 54.98M | 50.85M | 38.24M | 33.09M |
| BasicAverageShares | 54.98M | 50.85M | 38.24M | 33.09M |
| DilutedEPS | -0.43 | -0.50 | -0.36 | -0.39 |
| BasicEPS | -0.43 | -0.50 | -0.36 | -0.39 |
| DilutedNIAvailtoComStockholders | -23.49M | -25.65M | -13.89M | -12.77M |
| NetIncomeCommonStockholders | -23.49M | -25.65M | -13.89M | -12.77M |
| NetIncome | -23.49M | -25.65M | -13.89M | -12.77M |
| NetIncomeIncludingNoncontrollingInterests | -23.49M | -25.65M | -13.89M | -12.77M |
| NetIncomeContinuousOperations | -23.49M | -25.65M | -13.89M | -12.77M |
| PretaxIncome | -23.49M | -25.65M | -13.89M | -12.77M |
| OtherIncomeExpense | 1.19M | 1.31M | 7.35M | 550.00K |
| OtherNonOperatingIncomeExpenses | 1.19M | 1.31M | 7.35M | 550.00K |
| SpecialIncomeCharges | 6.88M | 0.00 | ||
| OtherSpecialCharges | -641.00K | |||
| RestructuringAndMergernAcquisition | -6.88M | 0.00 | ||
| OperatingIncome | -24.68M | -26.96M | -21.24M | -13.32M |
| OperatingExpense | 24.68M | 26.96M | 21.24M | 13.32M |
| ResearchAndDevelopment | 15.74M | 16.97M | 14.17M | 11.00M |
| SellingGeneralAndAdministration | 8.93M | 10.00M | 7.07M | 2.32M |
| GeneralAndAdministrativeExpense | 8.93M | 10.00M | 7.07M | 2.32M |
| OtherGandA | 8.93M | 10.00M | 7.07M | 2.32M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 59.23M | 51.03M | 50.74M | 50.73M |
| ShareIssued | 59.23M | 51.03M | 50.74M | 50.73M |
| TotalDebt | 19.31M | 20.70M | 955.00K | 1.81M |
| TangibleBookValue | 17.61M | 20.76M | 44.31M | 2.46M |
| InvestedCapital | 17.61M | 20.76M | 44.31M | 2.46M |
| WorkingCapital | 14.46M | 17.34M | 40.71M | 383.00K |
| NetTangibleAssets | 17.61M | 20.76M | 44.31M | 2.46M |
| CapitalLeaseObligations | 19.31M | 20.70M | 955.00K | 1.81M |
| CommonStockEquity | 17.61M | 20.76M | 44.31M | 2.46M |
| TotalCapitalization | 17.61M | 20.76M | 44.31M | 2.46M |
| TotalEquityGrossMinorityInterest | 17.61M | 20.76M | 44.31M | 2.46M |
| StockholdersEquity | 17.61M | 20.76M | 44.31M | 2.46M |
| GainsLossesNotAffectingRetainedEarnings | 48.00K | 140.00K | 35.00K | 0.00 |
| OtherEquityAdjustments | 48.00K | 140.00K | 35.00K | |
| RetainedEarnings | -121.92M | -98.44M | -72.79M | -58.90M |
| AdditionalPaidInCapital | 139.48M | 119.05M | 117.05M | 6.71M |
| CapitalStock | 6.00K | 5.00K | 5.00K | 54.65M |
| CommonStock | 6.00K | 5.00K | 5.00K | 54.65M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 23.95M | 25.04M | 6.82M | 2.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 17.96M | 19.31M | 0.00 | 902.00K |
| LongTermDebtAndCapitalLeaseObligation | 17.96M | 19.31M | 0.00 | 902.00K |
| LongTermCapitalLeaseObligation | 17.96M | 19.31M | 0.00 | 902.00K |
| CurrentLiabilities | 5.99M | 5.72M | 6.82M | 2.09M |
| CurrentDebtAndCapitalLeaseObligation | 1.35M | 1.38M | 955.00K | 910.00K |
| CurrentCapitalLeaseObligation | 1.35M | 1.38M | 955.00K | 910.00K |
| LineOfCredit | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 343.00K | 396.00K | 657.00K | 0.00 |
| PayablesAndAccruedExpenses | 4.29M | 3.94M | 5.21M | 1.18M |
| CurrentAccruedExpenses | 3.48M | 3.40M | 4.03M | 895.00K |
| Payables | 817.00K | 542.00K | 1.18M | 281.00K |
| AccountsPayable | 817.00K | 542.00K | 1.18M | 281.00K |
| TotalAssets | 41.56M | 45.80M | 51.13M | 5.45M |
| TotalNonCurrentAssets | 21.12M | 22.73M | 3.60M | 2.98M |
| OtherNonCurrentAssets | 1.47M | 1.39M | 1.37M | |
| NonCurrentPrepaidAssets | 52.00K | 275.00K | 200.00K | |
| NetPPE | 19.65M | 21.34M | 1.96M | 2.78M |
| AccumulatedDepreciation | -2.64M | -2.44M | -2.41M | -2.03M |
| GrossPPE | 22.29M | 23.79M | 4.37M | 4.82M |
| Leases | 0.00 | 12.00K | 12.00K | |
| ConstructionInProgress | 0.00 | 299.00K | 0.00 | |
| OtherProperties | 21.89M | 23.13M | 4.30M | 4.79M |
| MachineryFurnitureEquipment | 397.00K | 361.00K | 61.00K | 18.00K |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 20.44M | 23.06M | 47.53M | 2.47M |
| OtherCurrentAssets | 1.84M | 2.41M | 2.45M | 291.00K |
| PrepaidAssets | 291.00K | |||
| Receivables | 253.00K | 0.00 | ||
| TaxesReceivable | 253.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 18.35M | 20.65M | 45.08M | 2.18M |
| CashAndCashEquivalents | 18.35M | 20.65M | 45.08M | 2.18M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -21.34M | -24.59M | -19.12M | -11.52M |
| IssuanceOfDebt | 426.00K | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 18.82M | 0.00 | 16.00K | 11.62M |
| CapitalExpenditure | -556.00K | -887.00K | -338.00K | -572.00K |
| IncomeTaxPaidSupplementalData | 2.00K | 1.00K | 0.00 | 1.00K |
| EndCashPosition | 19.69M | 21.99M | 46.44M | 2.18M |
| BeginningCashPosition | 21.99M | 46.44M | 2.18M | 2.08M |
| EffectOfExchangeRateChanges | -14.00K | 3.00K | -1.00K | 0.00 |
| ChangesInCash | -2.29M | -24.45M | 44.27M | 97.00K |
| FinancingCashFlow | 19.05M | 133.00K | 63.39M | 11.62M |
| CashFlowFromContinuingFinancingActivities | 19.05M | 133.00K | 63.39M | 11.62M |
| NetOtherFinancingCharges | -189.00K | 63.37M | ||
| ProceedsFromStockOptionExercised | 0.00 | 133.00K | ||
| NetCommonStockIssuance | 18.82M | 0.00 | 16.00K | 11.62M |
| CommonStockIssuance | 18.82M | 0.00 | 16.00K | 11.62M |
| NetIssuancePaymentsOfDebt | 426.00K | 0.00 | 0.00 | |
| NetShortTermDebtIssuance | 426.00K | 0.00 | 0.00 | |
| ShortTermDebtIssuance | 426.00K | 0.00 | 0.00 | |
| InvestingCashFlow | -556.00K | -887.00K | -338.00K | -572.00K |
| CashFlowFromContinuingInvestingActivities | -556.00K | -887.00K | -338.00K | -572.00K |
| NetPPEPurchaseAndSale | -556.00K | -887.00K | -338.00K | -572.00K |
| PurchaseOfPPE | -556.00K | -887.00K | -338.00K | -572.00K |
| OperatingCashFlow | -20.79M | -23.70M | -18.79M | -10.95M |
| CashFlowFromContinuingOperatingActivities | -20.79M | -23.70M | -18.79M | -10.95M |
| ChangeInWorkingCapital | 354.00K | -1.29M | 338.00K | 436.00K |
| ChangeInOtherWorkingCapital | 204.00K | |||
| ChangeInOtherCurrentLiabilities | 14.00K | |||
| ChangeInPayablesAndAccruedExpense | 116.00K | -1.56M | 814.00K | 334.00K |
| ChangeInAccruedExpense | -132.00K | -955.00K | 2.75M | 321.00K |
| ChangeInPayable | 248.00K | -602.00K | -1.94M | 13.00K |
| ChangeInAccountPayable | 248.00K | -602.00K | -1.94M | 13.00K |
| ChangeInPrepaidAssets | 491.00K | 264.00K | -476.00K | 102.00K |
| ChangeInReceivables | -253.00K | 0.00 | ||
| OtherNonCashItems | 276.00K | 904.00K | -6.91M | -627.00K |
| StockBasedCompensation | 1.61M | 1.86M | 1.30M | 1.67M |
| AssetImpairmentCharge | 60.00K | 121.00K | ||
| DepreciationAmortizationDepletion | 400.00K | 357.00K | 381.00K | 345.00K |
| DepreciationAndAmortization | 400.00K | 357.00K | 381.00K | 345.00K |
| OperatingGainsLosses | 121.00K | -641.00K | ||
| GainLossOnSaleOfPPE | 121.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -23.49M | -25.65M | -13.89M | -12.77M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VANI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|